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ABSTRACT
Introduction Clinically diagnosed pneumonia in 
children is a leading cause of paediatric hospitalisation 
and mortality. The aetiology is usually bacterial or viral, 
but malaria can cause a syndrome indistinguishable 
from clinical pneumonia. There is no method with high 
sensitivity to detect a bacterial infection in these patients 
and, as result, antibiotics are frequently overprescribed. 
Conversely, unrecognised concomitant bacterial infection 
in patients with malarial infections occur with omission of 
antibiotic therapy from patients with bacterial infections. 
Previously, we identified two combinations of blood 
proteins with 96% sensitivity and 86% specificity for 
detecting bacterial disease. The current project aimed to 
validate and improve these combinations by evaluating 
additional biomarkers in paediatric patients with clinical 
pneumonia. Our goal was to describe combinations of 
a limited number of proteins with high sensitivity and 
specificity for bacterial infection to be incorporated in 
future point- of- care tests. Furthermore, we seek to explore 
signatures to prognosticate clinical pneumonia.
Methods and analysis Patients (n=900) aged 2–59 
months presenting with clinical pneumonia at two 
Gambian hospitals will be enrolled and classified according 
to criteria for definitive bacterial aetiology (based on 
microbiological tests and chest radiographs). We will 
measure proteins at admission using Luminex- based 
immunoassays in 90 children with definitive and 160 with 
probable bacterial aetiology, and 160 children classified 
according to the prognosis of their disease. Previously 
identified diagnostic signatures will be assessed through 
accuracy measures. Moreover, we will seek new diagnostic 
and prognostic signatures through machine learning 
methods, including support vector machine, penalised 
regression and classification trees.
Ethics and dissemination Ethics approval has been 
obtained from the Gambia Government/Medical Research 
Council Unit The Gambia Joint Ethics Committee (protocol 
1616) and the institutional review board of Boston 
University Medical Centre (STUDY00000958). Study results 
will be disseminated to the staff of the study hospitals, in 
scientific seminars and meetings, and in publications.
Trial registration number H- 38462.
INTRODUCTION
Clinical pneumonia may be caused by viral 
or bacterial infections1 and, where malaria 
is endemic, malaria can cause a syndrome 
indistinguishable from clinical pneumonia.2 
There has been a growing number of publi-
cations on biomarkers for the diagnosis of 
bacterial infections and to prognosticate 
outcomes in patients with clinical pneu-
monia.3–37 Such increased attention is driven 
by the need for low cost point- of- care (POC) 
tests able to accurately, reliably and promptly 
diagnose bacterial infections that can guide 
Strengths and limitations of this study
 ► This study will be conducted in a resource- limited 
country for future development of a point- of- care 
test for these settings.
 ► We will quantify known and recently identified bio-
markers that will be combined using different ma-
chine learning approaches.
 ► Children will be followed up for 30 days after dis-
charge to yield mid- term prognostic assessment of 
the clinical pneumonia.
 ► A difficulty shared by studies aiming to identify bio-
markers to diagnose bacterial infection is lack of an 
optimal gold standard for bacterial infection; thus, 
we will use a composite criterion based on microbi-
ological and radiological evidence of infection (pri-
mary criteria) and probable criteria based on expert 
evaluation of clinical and laboratory data.
 ► Although the sample size is relatively small, results 
will establish a benchmark against which the iden-
tified signatures in populations in other areas and in 
different subgroups, such as children with undernu-
trition, can be compared.
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treatment.38–41 All existing tests have delayed turnaround 
times or require specialised facilities that are often 
unavailable in resource- limited settings. POC tests can 
support timely decisions about treatment and ameliorate 
the overprescription of antibiotics to treat viral infections, 
thus slowing the progression of global antibiotic resis-
tance.42–46 In malaria endemic areas, antibiotics may also 
be ‘underprescribed’ and children with bacterial pneu-
monia may be mistakenly treated for malaria and not 
receive antibiotic therapy.43 47 Prognostic POCs could also 
guide referrals and allow prioritisation of intensive treat-
ment measures that are particularly scarce in resource- 
limited settings.
Symptoms of bacterial and viral diseases and of malaria 
often overlap.48 49 Radiographical evidence of pneumonia 
has been used as an endpoint in studies of pneumococcal 
vaccine, but chest X- rays, particularly in resource- limited 
settings, when available have moderate reliability50–58 and 
may result in both false- positive and false- negative results. 
Laboratory tests have low accuracy. Blood or pleural fluid 
cultures are highly specific for diagnosing bacterial infections 
but have low sensitivity, and results are not promptly avail-
able.59 60 Bacterial PCR tests require specialised resources 
and have low sensitivity. Viral PCR also requires specialised 
facilities and does not establish a diagnosis of viral pneu-
monia.49 61–63 Furthermore, in children, antigen detection in 
the urine has limited utility, and induced sputum samples 
are difficult to obtain and likely to be contaminated with 
the normal flora.64–67 Where malaria is endemic, standard 
malaria diagnostic tests can detect the parasite in blood. 
Nevertheless, malaria may coexist with other infections while 
not causing the respiratory syndrome.68 69
Generally, previous biomarker studies to diagnose bacte-
rial diseases or to prognosticate disease in patients with pneu-
monia or sepsis focused on procalcitonin (PCT) and/or C 
reactive protein (CRP) and concluded that the markers had 
moderate accuracy (area under the receiver operating char-
acteristic curve (AUC- ROC)<0.80).9–14 34–36 70–93 Accuracy of 
a single biomarker in bacterial pneumonia is probably low 
since many biomarkers may be in the inflammatory pathway 
triggered by several pathogens.94 More recently, studies 
screened through novel biomarkers and identified gene 
transcription signatures able to distinguish patients with 
bacterial and viral infections.95 96 Additionally, a biomarker 
signature based on haptoglobin (HP) and lipocalin (NGAL) 
has been identified to differentiate malaria and probable 
bacteria aetiology in paediatric patients with clinical pneu-
monia in a resource- limited country.97 Two other promising 
signatures to differentiate viral from bacterial infections in 
high- income countries (HICs) have been identified. The 
first (ImmunoXpert) is based on CRP, tumour necrosis 
factor- related apoptosis- inducing ligand (TRAIL) and inter-
feron gamma- induced protein 10 (IP- 10) and has been vali-
dated in HICs, with sensitivity ranging from 87% to 94% 
and specificity from 90% to 94%.5 98–101The second is based 
on CRP and Mixovirus Resistance Protein A and has been 
implemented in a POC (FebriDx) in HICs, with sensitivity 
and specificity varying from 80% to 96% and from 67% to 
94%, respectively.4 102 103 Although promising, these two 
signatures need to be validated in resource- limited settings 
where inflammatory responses may vary because of malaria, 
coinfections and undernutrition.104
In Mozambique, we scanned through several biomarkers 
and combined them through machine learning methods, 
aiming to detect bacterial infection (vs no bacterial infec-
tion) in paediatric patients with clinical pneumonia. Consid-
ering the potential of coexisting malaria infections, we 
sought biomarker signatures by comparing children with 
malaria, bacterial and viral infections and validated accu-
rate signatures by comparing patients with and without 
bacterial infections.105 Signatures with 3–5 proteins were 
identified that had high sensitivity for the diagnosis of bacte-
rial pneumonia (96%–91%) while misdiagnosing few viral 
cases. The selected signatures performed better than signa-
tures including commonly collected clinical and laboratory 
markers, as well as pneumonia with consolidation on X- ray. 
The current study builds on our previous findings and aims 
to validate previous diagnostic signatures identified by us and 
other groups, in addition to improving on signatures by scan-
ning through novel biomarkers in a different population in 
rural Gambia.
Biomarkers for signatures will be selected and combined 
using a comprehensive set of data mining approaches. 
To validate and improve on prior signatures and seek 
prognostic signatures, we will add some novel prom-
ising biomarkers such as resistin and lactoferrin.37 106 107 
At the end of this study, we expect to select signatures 
with excellent accuracy (≥93% sensitivity) that have the 
highest prognostic utility and composed of a limited 
number of biomarkers that can be developed in a POC 
test. Our focus is on identifying patients who need antibi-
otic therapy for bacterial diseases.
Study objectives
Specifically, this study aimed to
 ► Assess combinations of blood proteins to accurately 
and reliably diagnose bacterial pneumonia in paedi-
atric patients.
We expect that protein combinations that were iden-
tified in previous studies as accurate for diagnosing 
bacterial infection in patients with clinical pneumo-
nia will have high sensitivity, specificity and AUC- ROC 
in an African paediatric population different from the 
Mozambican children. Biomarkers of these signatures 
will be absent in healthy children. Moreover, we hy-
pothesise that accuracy of previous signatures can be 
improved by seeking to combine them with novel can-
didate proteins.
 ► Explore prognostic biomarker signatures in patients 
with clinical pneumonia caused by any pathogen.
We anticipate that combination of inflammato-
ry proteins in the blood measured at admission 
will accurately identify patients who will clinically 
deteriorate.




To test and identify existing and novel diagnostic 
biomarker signatures for bacterial disease, we will measure 
proteins in the blood at admission and collect clinical 
and laboratory information at admission to ascertain 
diagnostic groups. Diagnostic signatures will be sought 
by comparing children in the target diagnosis groups. To 
seek prognostic biomarker signatures, we will prospec-
tively follow clinical outcomes collected after admission 
and discharge. When studying prognostic signatures in 
the primary analysis, proteins will be compared across 
three groups with poor, moderate and good prognoses. 
The study started in February of 2019 and is expected to 
be concluded by November 2021.
Study environment
The study will be conducted at the Boston University 
School of Public Health (BUSPH), the Medical Research 
Council Unit The Gambia (MRCG) at London School of 
Hygiene & Tropical Medicine, and the Multiplex Core 
Facility of the Centre of Translational Immunology from 
the University Medical Centre Utrecht. Patients will be 
recruited at Basse and Bansang Hospitals. These hospi-
tals serve a population of 178 510 (224 villages) and 99 
113 (217 villages), respectively, with 19% of the popu-
lation aged <5 years. Diagnostic laboratory tests will be 
conducted at the MRCG, Basse Field Station. The multi-
plex bead- based immunoassay will be conducted at the 
Center for Translational Immunology/Utrecht Medical 
Center and analysis will be conducted at BUSPH.
Outcomes
Two sets of outcomes will be evaluated, one for each study 
aim.
Objective 1: diagnostic group classification
The primary objective of the diagnostic group classifica-
tion was to identify patients in need of antibiotic therapy 
for a bacterial infection and not to identify the pathogen 
responsible for the respiratory symptoms. Patients will be 
assigned to bacterial, malarial and viral groups according 
to a definitive classification (primary analysis) (figure 1) 
when seeking signatures, and bacterial and non- bacterial 
infection groups when testing signatures. Patients will 
also be categorised into bacterial and non- bacterial infec-
tion groups based on a probable classification criterion 
(secondary analysis). Patients with ambiguous diagnosis 
who do not meet our criteria will be excluded from the 
study of objective 1. By incorporating the two outcomes, 
we will assess the validity of the identified biomarker 
signatures in patients with and without detected bacter-
aemia and provide data to support the generalisability of 
the inflammatory biomarker signature.
Figure 1 Definitive and probable diagnostic classification criteria (gold standard of diagnostic signature aim) to assign patients 
to the MA, BA and VI groups (definitive composite criteria) and to the BA and NBA groups. BA, bacterial; MA, malaria; NBA, 
non- bacterial; NP, nasopharyngeal; VI, viral.
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For the definitive classification, a patient will be assigned 
to the bacterial (BA) group if he/she has a positive bacte-
rial pathogen culture of fluid from a normally sterile site 
(eg, blood or pleural fluid). Patients will be assigned 
to the viral (VI) group if they have negative bacteria 
microbiological tests, negative malaria blood slides, 
X- ray without ‘endpoint pneumonia’ (consolidation or 
pleural effusion51), no evidence of fungal infection, and 
positive PCR for a viral pathogen from nasopharyngeal 
swabs (NPS). Patients will be assigned to the malarial 
(MA) group if they have normal X- ray (with neither infil-
trates nor endpoint pneumonia), no bacterial infection 
and >0/µL asexual Plasmodium falciparum parasites if they 
are aged <1 year or >2500 asexual parasites/µL of blood if 
they are aged >1 year. Patients who are admitted with viral 
infections but who develop a secondary bacterial pneu-
monia during hospitalisation will be excluded from the 
VI group.
Patients with HIV infection or exposure (<1 year old) 
will be categorised as fungal pneumonia if they have chest 
X- ray with bilateral/symmetrical reticular or granular 
opacities without lobar consolidation and severe hypoxia 
(≤85% at admission) or positive NPS PCR for Pneumo-
cystis jiroveci or a blood culture positive to any pathogenic 
fungal micro- organism.
For the diagnostic categorisation of probable bacte-
rial pneumonia, patients will be assigned to the probable 
BA group based on review of data by an expert panel 
including paediatricians and infectious diseases special-
ists with at least 10 years of experience. Data will include 
clinical information collected at and during admission, 
chest X- ray results, full blood cell counts (FBCs), malaria 
microscopy and/or rapid diagnostic test (mRDT), bacteria 
culture, viral NPS, and other laboratory test results, when 
available, for example, urinalysis. Two experts will review 
patient data, independently and blindly, classifying 
patients as ‘certainly’ BA or non- bacterial (NBA), ‘prob-
able’ BA or NBA, ‘unclear’ BA or NBA. Only patients 
with consensual certainly or probable diagnosis will be 
included in this analysis.
Objective 2: poor prognosis
Poor prognosis will be primarily based on a three- category 
outcome recorded during and after hospitalisation. Addi-
tionally, we will explore secondary outcomes associated 
with a poor evolution of the clinical pneumonia during 
the first 5 days of hospitalisation, at discharge and 30 days 
after admission.
For the three- category outcome, regardless of the original 
infection, patients will be selected from the following 
three groups: group a, children who die during or up to 
30 days after admission; group b, children with prolonged 
hospital stay (>7 days) or who need to have antibiotic 
therapy changed within 48 hours of admission, or who are 
readmitted within 30 days after the first admission with 
symptoms associated with the first admission; and group 
c, children discharged well within 3 days of admission and 
without the need for a change in antibiotic therapy after 
admission. Secondary outcomes of clinical deterioration 
will be (1) area under the first 5 days of the oxygen satu-
ration curve; (2) necessity to change antibiotic therapy 
within the first 2 days from admission or to receive oxygen 
therapy when it was not required at admission and (3) 
duration of hospital admission.
Participants
We will enrol 900 patients with clinical pneumonia aged 
2–59 months by January 2021, assuming we will have 
approximately 30 patients with a definitive diagnosis of 
bacterial infection, 30 with malaria and 30 with viral infec-
tions (figure 1). Among the 900 patients, we anticipate 
enrolling 60 and 100 patients with and without probable 
bacterial infection, respectively.
For the study of prognostic biomarkers (figure 2), we 
will include 160 patients. All deaths during or up to 30 
days from admission will be selected, and the remaining 
sample size will be divided between the other two cate-
gory outcomes, that is, group b, prolonged admission, 
readmission or changed antibiotics during admission, 
and group c, discharged within 3 days with improvement 
of symptoms. To meet the target sample size in the groups 
b and c, eligible children will be randomly selected.
A total of 20 community healthy control children aged 
2–59 months without any symptoms or signs and no 
malaria infection will be enrolled in vaccination clinics in 
Basse to assess precision of signatures.
Patient and public involvement
Patients and the public were not involved in the design of 
this research.
Inclusion and exclusion criteria
Paediatric patients aged 2–59 months will be screened 
and will be enrolled if they present with cough or difficult 
breathing, the guardians provide informed consent, are 
referred for probable admission, and have at least one 
of the following signs: increased respiratory rate for age 
based on the WHO criteria, lower chest indrawing, periph-
eral arterial oxygen saturation <93% (measured by pulse 
oximetry), grunting, nasal flaring or undernutrition. The 
WHO criteria for increased respiratory rate are respiratory 
rate ≥50 breaths/min for children 2–11 months old; and 
respiratory rate ≥40 breaths/min for children 1–5 years 
old.108 Undernutrition will be defined as visible wasting 
or middle upper arm circumference <11.5 cm if aged ≥6 
months or weight- for- height Z- scores of <−3. Patients will 
be excluded if they have suspected tuberculosis based on 
a cough lasting >2 weeks, were admitted to a hospital in 
the previous 2 weeks and have evidence of any condition 
that could be worsened by collection of blood.
Healthy community controls will be enrolled if an 
mRDT is negative; vaccines have not been administered 
that day; there are no symptoms of any disease; and there 
is no history of hospital admission in the previous 4 weeks. 
Healthy controls will be excluded if they are later found to 
have malaria infection detected by a positive microscopy.
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Recruitment and follow-up
On arrival at any of the study hospitals, patients aged 
2–59 months will be screened for the presence of respi-
ratory symptoms and undernutrition by a senior research 
nurse with extensive experience in research in paediatric 
pneumonia (figure 1). If they pass this first- level assess-
ment, they will be referred to a second research nurse 
for a detailed medical history and physical examination. 
Those patients who are considered eligible will undergo 
informed consent procedures.
After informed consent, patients will be referred for 
clinical examination and admission procedures by a 
research clinician and then for sample collection and 
chest X- ray. NPS will be performed and 5 mL of venous 
blood will be drawn (never more than 3 mL/kg per WHO 
standard109 with 3 mL immediately placed into one paedi-
atric blood culture bottle (Pedibact; BD, Franklin Lakes, 
New Jersey, USA) and the remaining 2 mL placed in an 
EDTA vacutainer. From the EDTA tube, a drop of blood 
will be used for haemoglobin rapid test and mRDT, both 
part of standard of care in the Gambia. Other tests based 
on standard of care may be conducted, including urinal-
yses, glucose, examination of cerebrospinal fluid (CSF) 
and pleural fluid, or lung aspirate. We will follow local 
clinical practice and HIV testing will not be routinely 
conducted. HIV prevalence is approximately 1% in ante-
natal surveys in The Gambia. Blood in EDTA will be 
processed and used within 1 hour from collection for 
FBC, malaria microscopy, and will be centrifuged and 
aliquoted to store plasma at −80C in the MRCG biobank 
for the multiplex bead- based immunoassay. An aliquot of 
150 µL will be sent to the Centre of Translational Immu-
nology in Utrecht for quantification of proteins with 
temperature controlled dry ice shipment.
Follow-up
After admission, patients will be followed up daily for 5 
days to record pulse oximetry, antibiotic therapy, feeding, 
clinical deterioration with need for additional tests. 
If patients are receiving oxygen during the follow- up 
visits, they will have their lowest recorded pulse oxim-
etry imputed. At hospital separation, a research nurse 
will fill a case report form (CRF) to record diagnosis and 
outcome (eg, death, absconding or discharge alive and 
well). Moreover, for patients who are discharged, a phone 
call will be placed to the parent/guardian 30 days after 
admission.
Study measurements and procedures
 ► Bacterial culture: approximately 3 mL will be incu-
bated in an automatic BACTEC 9050 system (BD) for 
a minimum of 4 days. Positive blood cultures will be 
examined by Gram stain and subcultured onto blood 
agar, chocolate agar or MacConkey agar plates based 
on Gram stain. Bacterial growth will be defined as 
contaminant when bacteria generally considered skin 
flora are isolated from the positive blood culture (eg, 
coagulase- negative Staphylococci, Bacillus species or 
Micrococci).110 Lung fluids will be cultured according 
to procedures previously described.111
Figure 2 Exploratory primary (A) and secondary (B) prognosis outcomes.
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 ► Culture of CSF, lung aspirate and pleural fluid aspi-
rate: cell count and direct gram reaction will be 
performed as well as bacterial antigen latex agglu-
tination test. A 50–100 µL aliquot of the specimen 
will be inoculated onto blood agar, chocolate agar 
and MacConkey Agar plates for isolation of bacterial 
growth.
 ► Viral PCR of NPS: NPS will be placed in media that 
will be aliquoted and stored at −80°C for real time 
polymerase chain reaction (rtPCR). Assays will use 
primers and probes for influenza virus types A and B, 
respiratory syncytial virus types A and B, adenovirus, 
parainfluenza viruses 1, 2, 3 and 4, human metap-
neumovirus, coronavirus, bocavirus, swine influenza 
virus and rhinovirus. P. jiroveci will also be screened in 
this PCR. Viral RNA and DNA will be extracted from 
supernatant of NPS samples using the QIAamp cador 
Pathogen Mini Kit or the Qiacube HT manufactured 
by Qiagen and PCR reactions will be ran as described 
elsewhere.112 PCR for SARS- CoV- 2 is not planned 
because paediatric pneumonia caused by SARS- CoV- 2 
is generally rare and clinical cases of COVID- 19 in 
adults have been rare in the region. However, if future 
evidence suggests that SARS- CoV- 2 shall be consid-
ered as a pathogen of paediatric clinical pneumonia, 
SARS- CoV- 2 PCR may be performed.
 ► Malarial microscopy: thick blood smear slides will be 
read blindly by two microscopists and, if discrepant, 
by a third.
 ► FBC: FBC will be performed on a Medonic M51 five- 
part haematology analyser (Boule Diagnostics AB, 
Domnarvsgatan, Spanga, Sweden). The parameters 
measured will be white blood cell count, absolute and 
per cent count of lymphocytes, monocytes, neutro-
phils, eosinophils, basophils, red blood cell count, 
platelet count, haemoglobin, mean cell volume, 
haematocrit, red cell distribution width, mean cell 
haemoglobin, mean corpuscular haemoglobin 
concentration and mean platelet volume.
 ► Multiplex Bead- Based Immunoassay: using Luminex 
technology will quantify proteins in plasma and will 
be conducted at the Multiplex Core Facility of the 
Centre of Translational Immunology ISO9001:2015 
laboratory using FlexMAP3D systems.113 A total of 50 
proteins will be included in the assay: (1) proteins 
identified in our previous study to constitute accu-
rate signatures (eg, HP, interleukin (IL)- 10 and 
IL- 18 and tissue inhibitor of metalloproteinases 1, 
tumour necrosis factor receptor 2 and resistin)114; 
(2) proteins that discriminated the three groups 
in high- throughput scans conducted previously 
(eg, bactericidal/permeability- increasing protein, 
lactotransferrin, granulocyte colony- stimulating 
factor and matrix metallopeptidase 9); (3) proteins 
specified in previous studies and listed previously (eg, 
NGAL, PCT, TRAIL and IP- 10), and proteins identi-
fied in previous studies listed earlier with prognostic 
value (eg, angiopoietin).
 ► Chest radiographs: frontal radiographs will be 
obtained, and images will be recorded in a computer 
file. Radiographical findings will be classified as 
proposed by Cherian et al51 into the presence of consoli-
dation, pleural fluid, other infiltrates or normal. Addi-
tionally, the presence of reticular/reticulonodular 
patterns, cavities, pneumatoceles, lymphadenopathy, 
abscess, focal fibrosis, pneumothorax, cardiomegaly 
and foreign body will be noted. Chest X- rays will be 
read by two clinicians and, if discrepant for consolida-
tion, they will be adjudicated by a third reader, all with 
training in radiographical interpretation for pneu-
monia and calibration against WHO standard images. 
Also, a pulmonologist will read a sample of 10% of 
X- rays for quality assurance and control.
Data management
All data will be captured through laptops/desktop 
computers using an electronic medical record system 
(EMRS) developed at the MRCG. The only exception will 
be for follow- up of admitted patients who will be captured 
on paper forms and later entered in the EMRS. During 
power outages, paper forms will be completed and, when 
electricity is back, data will be entered into the EMRS. To 
ensure data quality, data validation rules have been estab-
lished in the EMRS that generates alert messages. Addi-
tionally, a complete process flow has been established to 
sequentially activate forms for entry, and a report listing 
missing variables is generated during entry of forms to 
assure form completeness.
Data analysis
Descriptive analysis will be conducted to seek outliers and 
to assess assumptions for tests and appropriate transfor-
mations. Patient severity scores at baseline will be derived 
based on principal component analysis, including base-
line clinical and laboratory variables. These scores will 
be included in the analysis and used to explore stratifi-
cation of patients in the study of diagnostic biomarker 
signatures. Adjustments for potential confounders (eg, 
overall and cell- specific leucocyte counts, breast feeding 
and undernutrition) and assessment of heterogeneity 
across subgroups will be done by incorporating the factor 
in analysis.
In analysis of objective 1, we will first test previous diag-
nostic biomarker signatures5 105 through estimating AUC- 
ROC, sensitivity and specificity with 95% CI. Using levels 
of biomarkers included in Valim et al105 and Oved et al,98 
we will reproduce signatures using the original models. 
To discover alternative biomarker signatures, we will start 
by conducting single biomarker analysis in which we will 
rank individual markers by pairwise comparisons of the 
three definitive diagnosis groups (primary analysis) and 
the two bacterial versus non- bacterial probable diagnosis 
groups (secondary analysis) and estimation of AUC- ROC 
with 95% CI.115 We will also estimate sensitivity and speci-
ficity for an optimal cut- off (weighting towards high sensi-
tivity to bacteria) based on comparison of the BA and NBA 
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definitive diagnosis groups through resampling. Next, to 
identify composite biomarkers, all markers (including 
clinical and laboratory tests and severity scores) will be 
combined and selected through comparison of the three 
definitive diagnosis groups using logistic regression with 
elastic net; classification or regression trees depending 
on the specific outcome; and support vector machine 
(SVM). In the SVM, non- linear radial basis function 
kernels will be used and features will be selected through 
a penalisation and recursive feature elimination.116 117 
We will train models and identify signatures based on the 
three diagnosis groups, although the focus is in classifi-
cation of BA and NBA (defined as MA or VI diagnosis) 
because using three groups, we found that signatures are 
likely to be more accurate when markers are not mono-
tonically increasing or decreasing across groups. For 
instance, if a marker is high in BA, low in VI and high 
in MA, levels of VI with MA are suboptimally averaged 
when VI and MA are collapsed for training signatures. 
Within each class of models, tuning parameters will be 
obtained through a metric of misclassification (eg, devi-
ance or error) estimated in fivefold cross validation. Addi-
tionally, models will be selected based on a biased choice 
of tuning parameters (those determining ≤5 markers). 
Penalties for missing a bacterial infection will be used. 
Models will be tested by estimating accuracy to diagnose 
BA versus non- BA in the definitive diagnosis classification 
using resampling. Moreover, accuracy will be estimated by 
comparing BA with NBA probable diagnosis groups.
Analyses of objective 2 will use categorical or continuous 
surrogates of poor prognosis as outcomes and markers as 
predictors. Markers will be measured at admission. Signa-
tures will be sought and tested using the same models of 
objective 1.
To estimate precision, we will report the coefficient of 
variation (CV) of selected biomarkers in healthy controls. 
Contaminated cultures will be considered negative. In 
immunoassays, samples <lowest limit of quantification 
(LLOQ) or > highest limit of quantification (HLOQ) will 
be assigned a value below and above the limits of quantifi-
cation, respectively, through a uniform distribution.
An α- significance level of 0.05 will be used. In single- 
marker analysis, p values and CIs will be adjusted for 
family- wise error rate through permutation or false 
discovery rate through Benjamin- Rocheberg, depending 
on the analysis.118
Sample size justification
We plan to enrol 900 patients to obtain 30 patients 
with confirmed bacterial disease based on expectations 
that ~3% of patients will have a positive bacterial culture 
for objective 1. Also, we anticipate that 30 patients will 
meet definitive viral or malarial aetiology. If necessary, we 
will randomly sample patients from the viral and malarial 
groups. The choice of 30 patients with and 60 patients 
without bacterial disease was based on feasibility consid-
erations, as was the choice of 20 healthy controls and 
160 patients in the analysis of the ‘probable’ diagnosis 
categories (a random stratified sample from all available 
subjects). However, with ~90 patients and only 23 patients 
with bacterial infections, we could previously identify 
accurate signatures.105 We anticipate that in objective 1, 
accuracy of previously identified signatures will be esti-
mated with relatively narrow CIs (table 1). For healthy 
controls, studying 20 patients will yield a 0.18 CI range 
for a CV of 0.20 with 0.80 assurance.119 Analysis of objec-
tive 2 will include a larger number of patients than objec-
tive 1 and shall yield precise CIs and more stable cross 
validation- based estimates.
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